Bingshan Li

Vanderbilt University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Recent advances in high-throughput single-cell technologies have enabled characterization of cellular states across distinct omics layers, yielding complementary insights into the organization of biological systems. To jointly leverage these disparate modalities, computational methods have been developed to align non-overlapping cell populations profiled in different omics layers, a task known as diagonal integration, thereby facilitating more fine-grained biological interpretations. However, existing integration approaches unrealistically assume that all cells are alignable and treat prior-knowledge-derived feature correspondences as fully reliable, retaining them unrefined throughout the alignment process. In this work, we introduce scCotag , a co-optimal transport (COOT)-based deep learning frame-work for diagonal integration of single-cell multi-omics data, to address these limitations. scCotag first infers cell alignment and feature correspondence with prior-informed COOT in an iterative manner, and then leverages the resulting transport plans to jointly learn cell and feature embeddings via regularized barycentric mapping and graph reweighting. Systematic benchmarking on human brain, bone marrow, and blood single-cell RNA-seq and ATAC-seq datasets demonstrates the overall superior performance of scCotag over state-of-the-art methods in both cell alignment accuracy and embedding accuracy. In particular, scCotag excels in simulated imbalance scenarios where not all cells are alignable. Applying scCotag to data in postmortem brains of Alzheimer’s disease (AD) and non-AD (NoAD) patients further yields more fine-grained biological interpretation of regulatory mechanisms. Together, these results demonstrate that scCotag provides a robust framework for single-cell diagonal integration and regulatory inference.

Year:

2025

Supplemental Figure S2. Meta-analysis full forest plots from AABCG for rs2814778 in relation to risk of breast cancer overall, ER- and TNBC. Figure shows non-significant odds ratio (OR) estimates for breast cancer risk overall, ER- and TNBC for ACKR1/DARC variant, rs2814778 in reference to controls.

Year:

2025

Background: Immune response in blood varies by ancestry, linked to an African-specific variant (rs2814778) in the Duffy Antigen Receptor for Chemokines ( DARC / ACKR1 ) gene. We examined associations between rs2814778, CD8 + T-cell density in breast tumors, and breast cancer risk in African-American/Black women. Methods: CD8 + T-cell density in tumors from 428 Black women were examined in relation to the rs2814778 variant. In the African Ancestry Breast Cancer Genetics (AABCG) Consortium with 16,886 cases and 18,044 controls, rs2814778 was evaluated in relation to risk of overall breast cancer and to more aggressive subtypes [estrogen receptor-negative (ER−) and triple-negative breast cancer (TNBC)]. Results: Women with the African-specific CC genotype had lower tumor CD8 + T-cell density (87.0 per mm 2 ) than those with TT genotypes (146.6 per mm 2 ; P T allele was significantly associated with an increase in T-cell density ( P = 0.04). In the largest analysis, to date, there were no associations between rs2814778 and risk of overall breast cancer [OR = 0.90 (95% confidence interval (CI), 0.66–1.22)] or with ER− breast cancer [OR = 0.86 (95% CI, 0.68–1.08)] or TNBC [OR = 0.77 (95% CI, 0.56–1.05)]. Conclusions: Although breast tumors from women with the African-specific DARC C allele had lower CD8 + T-cell density levels than those with T alleles, in a large breast cancer consortium with adequate statistical power, the variant was not associated with breast cancer risk overall, nor with risk of ER− breast cancer or TNBC, as previously hypothesized. Impact: Although the “Duffy-null” allele has been the focus of research as a contributor to aggressive breast cancer in Black women, this study with 34,930 cases and controls found no associations with risk.

Year:

2025

Supplemental Figure S1. Log-transformed CD8+ T-cell density per mm2 by ACKR1/DARC genotype. Figure displays box plot distribution of CD8+ T-cell density per mm2 according to ACKR1/DARC genotype (N=428).

Year:

2025

Schizophrenia (SCZ) is highly polygenic, and its biological underpinnings remain unclear. In this study, a cost‐effective strategy of including sub‐threshold GWAS (subGWAS) loci (i.e., 5 × 10 −8 < P ≤ 10 −6 ) in analysis is explored to increase the inference power of novel pathways. A total of 180 subGWAS loci are identified from SCZ GWAS studies and are shown to contain substantial true genetic association signals. By jointly modeling GWAS (sigGWAS) and subGWAS loci, 304 high‐confidence risk genes (HRGs) are identified, as well as a novel category of biological processes detected only in subGWAS loci, i.e., dendrite development and morphogenesis (DDM). Two candidate DDM genes ( CUL7 and DCC ), whose risk alleles in GWAS are associated with increased expression, are examined, and it is observed that upregulation of these genes leads to reduced neurite length. It is further revealed that the DDM genes lead to disrupted regulatory programs of the transcription factors CUX1/2 and NEUROD1 . Collectively, the study identifies DDM as a novel biological process in SCZ susceptibility, with particular implications for DCC ‐ and CUL7 ‐mediated alterations in neurite development and reveals regulatory programs involved in perturbation of the two candidate genes.

Year:

2025

Identifying risk genes associated with complex traits remains challenging. Integrating gene expression data with Genome-Wide Association Study (GWAS) through Transcriptome-Wide Association Study (TWAS) methods has discovered candidate risk genes for various complex traits. Splicing, which explains a comparable heritability of complex traits as gene expression, is under-explored due to its multidimensionality. To leverage multiple splicing events in a gene and shared splicing across tissues, we develop Multi-tissue Splicing Gene (MTSG), which employs tensor decomposition and sparse Canonical Correlation Analysis (sCCA) to extract meaningful information from high-dimensional multiple splicing events across multiple tissues. We build MTSG models using GTEx data and apply them to GWAS summary statistics of Alzheimer’s disease (AD) (111,326 cases and 677,663 controls) and schizophrenia (SCZ) (36,989 cases and 113,075 controls). We identify 174 and 497 significant splicing-mediated risk genes for AD and SCZ, respectively, at Bonferroni correction. For AD, our results demonstrate significant enrichment of AD related pathways and identify additional AD risk genes not detected in the single-tissue analysis, while preserving most top genes identified in the brain frontal cortex. Consistently, for SCZ, genes identified by our brain-wide MTSG model, built from a cluster of 13 brain tissues, exhibit stronger enrichment in SCZ-relevant genes and MTSG identifies unique SCZ risk genes compared to single-tissue models. These results showcase that our MTSG models capture distinctive splicing events across tissues, which might be overlooked when using single tissue alone. Our MTSG models can be applied to other complex traits to help identify splicing-mediated disease risk genes.

Year:

2025

Background Several health conditions are known to increase the risk of Alzheimer’s disease (AD). We aim to systematically identify medical conditions that are associated with subsequent development of AD by leveraging the growing resources of electronic health records (EHRs). Methods This retrospective cohort study used de-identified EHRs from two independent databases (MarketScan and VUMC) with 153 million individuals to identify AD cases and age– and gender-matched controls. By tracking their EHRs over a 10-year window before AD diagnosis and comparing the EHRs between AD cases and controls, we identified medical conditions that occur more likely in those who later develop AD. We further assessed the genetic underpinnings of these conditions in relation to AD genetics using data from two large-scale biobanks (BioVU and UK Biobank, total N=450,000). Results We identified 43,508 AD cases and 419,455 matched controls in MarketScan, and 1,320 AD cases and 12,720 matched controls in VUMC. We detected 406 and 102 medical phenotypes that are significantly enriched among the future AD cases in MarketScan and VUMC databases, respectively. In both EHR databases, mental disorders and neurological disorders emerged as the top two most enriched clinical categories. More than 70 medical phenotypes are replicated in both EHR databases, which are dominated by mental disorders (e.g., depression), neurological disorders (e.g., sleep orders), circulatory system disorders (e.g. cerebral atherosclerosis) and endocrine/metabolic disorders (e.g., type 2 diabetes). We identified 19 phenotypes that are either associated with individual risk variants of AD or a polygenic risk score of AD. Conclusions In this study, analysis of longitudinal EHRs from independent large-scale databases enables robust identification of health conditions associated with subsequent development of AD, highlighting potential opportunities of therapeutics and interventions to reduce AD risk.

Year:

2025

Motivation Analysis of whole-genome sequencing (WGS) for genetics is still a challenge due to the lack of accurate functional annotation of non-coding variants, especially the rare ones. As eQTLs have been extensively implicated in the genetics of human diseases, we hypothesize that rare non-coding variants discovered in WGS play a regulatory role in predisposing disease risk. Results With thousands of tissue- and cell-type-specific epigenomic features, we propose TVAR. This multi-label learning-based deep neural network predicts the functionality of non-coding variants in the genome based on eQTLs across 49 human tissues in the GTEx project. TVAR learns the relationships between high-dimensional epigenomics and eQTLs across tissues, taking the correlation among tissues into account to understand shared and tissue-specific eQTL effects. As a result, TVAR outputs tissue-specific annotations, with an average AUROC of 0.77 across these tissues. We evaluate TVAR’s performance on four complex diseases (coronary artery disease, breast cancer, Type 2 diabetes and Schizophrenia), using TVAR’s tissue-specific annotations, and observe its superior performance in predicting functional variants for both common and rare variants, compared with five existing state-of-the-art tools. We further evaluate TVAR’s G-score, a scoring scheme across all tissues, on ClinVar, fine-mapped GWAS loci, Massive Parallel Reporter Assay (MPRA) validated variants and observe the consistently better performance of TVAR compared with other competing tools. Availability and implementation The TVAR source code and its scores on the ClinVar catalog, fine mapped GWAS Loci, high confidence eQTLs from GTEx dataset, and MPRA validated functional variants are available at https://github.com/haiyang1986/TVAR. Supplementary information Supplementary data are available at Bioinformatics online.

Year:

2022

Collaborators (14)

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Christine Ambrosone

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Song Yao

Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Katie O'Brien

Staff Scientist

National Institute of Environmental Health Sciences

UNITED STATES
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Clarice Weinberg

Principal Investigator

National Institute of Environmental Health Sciences

UNITED STATES
View details

Wei Zheng

-

UNITED STATES
View details

Yara G Abdou

University of North Carolina at Chapel Hill

UNITED STATES
View details

Zhijun Yin

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Chi-Chen Hong

Associate Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Dezheng Huo

University of Chicago

UNITED STATES
View details

Xingyi Guo

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Jo Freudenheim

SUNY Distinguished Professor and Associate Dean

University at Buffalo

UNITED STATES
View details

Elisa Bandera

Chief

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details